

## Reference Materials

<http://www.phppo.cdc.gov/dls/master/default.asp>

MASTER website for antimicrobial susceptibility testing – includes links to some materials referenced in teleconference

<http://www.cdc.gov/ncidod/hip/Lab/LAB.HTM>

CDC antimicrobial susceptibility testing fact sheets

<http://www.phppo.cdc.gov/nltn/default.aspx>

NLTN website – find out about additional courses/materials offered by NLTN

<http://www.asm.org/division/c/index.htm>

ASM Division C (clinical microbiology) website includes

“Askit” feature.. ask an “expert” about any question related to clinical microbiology!!!

“Division C Listserve” –join to see Q&A asked/answered by your peers!!!

<http://www.cdc.gov/mmwr/>

CDC MMWR – go here to subscribe for free!

<http://www.phppo.cdc.gov/clia/default.asp>

CLIA regulations

<http://www.idsociety.org/>

Infectious Diseases Society of America (IDSA)

<http://www.tufts.edu/med/apua/>

Alliance for Prudent Use of Antibiotics (APUA)

<http://www.fda.gov/cder/>

FDA – locate information on new and old antimicrobial agents here; consumer information also

## Texts and Other

Gilbert, D. N., R. C. Moellering, G. M. Eliopoulos, and M. A. Sande (eds). 2004. *The Sanford Guide to Antimicrobial Therapy, 2004*. 34th ed. Antimicrobial Therapy, Inc., Hyde Park, VT. ([www.Sanfordguide.com](http://www.Sanfordguide.com))

Isenberg, H. I. (ed). 2004. *Clinical Microbiology Procedures Handbook*, 2<sup>nd</sup> edition. Section 5. ASM Press, Washington, DC. ([www.asmpress.org](http://www.asmpress.org))

Livermore, D. M., T. G. Winstanley, and K. P. Shannon. 2001. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. *J Antimicrob Chemother.* 48:87-102.

Mandell, G. L., R. G. Douglas, R. Dolin and J. E. Bennett. 2005. *Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases*, 6th edition. Churchill Livingstone, Philadelphia.

Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken, (eds). 2003. *Manual of Clinical Microbiology*, 8<sup>th</sup> ed. pp. 1037-1212. ASM Press, Washington, DC. ([www.asmpress.org](http://www.asmpress.org))

CLSI/NCCLS Standards ([www.nccls.org](http://www.nccls.org))

- M2-A8 (M2). 2003. Performance standards for antimicrobial disk susceptibility tests. Eighth edition. Approved Standard.
- M7-A6 (M7). 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Sixth edition. Approved Standard.
- M100-S15 (M100). 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement.

*Portions were reproduced with permission from CLSI/NCCLS publication M100-S15 – Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement (ISBN 1-56238-556-9). Copies of the current edition may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.*

### Newer Antimicrobial Agents

Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. *Clin Infect Dis.* 38:994-1000.

Fenton, C., G. M. Keating, and M. P. Curran. 2004. Daptomycin. *Drugs.* 64:445-55; discussion 457-8.

Wellington, K., and S. Noble. 2004. Telithromycin. *Drugs.* 64:1683-94; discussion 1695-6.

Zuckerman, J. M. 2004. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. *Infect Dis Clin North Am.* 18:621-49.

### ***Proteus mirabilis* and ESBLs**

de Champs, C., R. Bonnet, D. Sirot, C. Chanal, and J. Sirot. 2000. Clinical relevance of *Proteus mirabilis* in hospital patients: a two year survey. *J Antimicrob Chemother.* 45:537-9.

Luzzaro, F., M. Perilli, G. Amicosante, G. Lombardi, R. Belloni, A. Zollo, C. Bianchi, and A. Toniolo. 2001. Properties of multidrug-resistant, ESBL-producing *Proteus mirabilis* isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations. *Int J Antimicrob Agents.* 17:131-5.

Mutnick, A. H., P. J. Turner, and R. N. Jones. 2002. Emerging antimicrobial resistances among *Proteus mirabilis* in Europe: report from the MYSTIC program (1997-2001). Meropenem yearly susceptibility test information collection. *J Chemother.* 14:253-8.

Nagano, N., N. Shibata, Y. Saitou, Y. Nagano, and Y. Arakawa. 2003. Nosocomial outbreak of infections by *Proteus mirabilis* that produces extended-spectrum CTX-M-2 type beta-lactamase. *J Clin Microbiol.* 41:5530-6.

Pagani, L., R. Migliavacca, L. Pallecchi, C. Matti, E. Giacobone, G. Amicosante, E. Romero, and G. M. Rossolini. 2002. Emerging extended-spectrum beta-lactamases in *Proteus mirabilis*. *J Clin Microbiol.* 40:1549-52.

Schwaber, M. J., P. M. Raney, J. K. Rasheed, J. W. Biddle, P. Williams, J. E. McGowan, Jr., and F. C. Tenover. 2004. Utility of NCCLS guidelines for identifying extended-spectrum beta lactamases in non-*Escherichia coli* and non-*Klebsiella* spp. of Enterobacteriaceae. *J. Clin. Microbiol.* 42:294-298.

### **Colistin / Polymyxin B and Multi-drug Resistant Gram-Negative Bacilli**

Denton, M., K. Kerr, L. Mooney, V. Keer, A. Rajgopal, K. Brownlee, P. Arundel, and S. Conway. 2002. Transmission of colistin-resistant *Pseudomonas aeruginosa* between patients attending a pediatric cystic fibrosis center. *Pediatr Pulmonol.* 34:257-61.

Gales, A.C., A.O. Reis, and R.N. Jones. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. *J Clin Microbiol.* 39:183-46.

Jones, R. N., H. S. Sader, and M. L. Beach. 2003. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). *International Journal of Antimicrobial Agents.* 22:551-556.

Linden, P. K., S. Kusne, K. Coley, P. Fontes, D. J. Kramer, and D. Paterson. 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant *Pseudomonas aeruginosa*. *Clin Infect Dis.* 37:154-60.

Sobieszczyk, M. E., E. Y. Furuya, C. M. Hay, P. Pancholi, P. Della-Latta, S. M. Hammer, and C. J. Kubin. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. *J Antimicrob Chemother.* 54:566-9.

Urban, C., S. Segal-Maurer, and J. J. Rahal. 2003. Considerations in control and treatment of nosocomial infections due to multidrug-resistant *Acinetobacter baumannii*. *Clin Infect Dis.* 36:1268-74.

Yoon, J., C. Urban, C. Terzian, N. Mariano, and J. J. Rahal. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 48:753-757.

### ***Neisseria meningitidis***

Richter, S. S., K. A. Gordon, P. R. Rhomberg, M. A. Pfaller, and R. N. Jones. 2001. *Neisseria meningitidis* with decreased susceptibility to penicillin: Report from the SENTRY antimicrobial surveillance program, North America, 1998-99. *Diagn Microbiol Infect Dis.* 41:83-88.

Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. *NEJM.* 344:1378-1388.

van Deuren, M., P. Brandtzaeg, and J. W. van der Meer. 2000. Update on meningococcal disease with emphasis on pathogenesis and clinical management. *Clin Microbiol Rev.* 13:144-66.

### ***Staphylococcus lugdunensis***

De Paulis, A. N., S. C. Predari, C. D. Chazarreta, and J. E. Santoiani. 2003. Five-test simple scheme for species-level identification of clinically significant coagulase-negative staphylococci. *J Clin Microbiol.* 41:1219-24.

Ebright, J. R., N. Penugonda, and W. Brown. 2004. Clinical experience with *Staphylococcus lugdunensis* bacteremia: a retrospective analysis. *Diagn Microbiol Infect Dis.* 48:17-21.

Schnitzler, N., R. Meilicke, G. Conrads, D. Frank, and G. Haase. 1998. *Staphylococcus lugdunensis*: report of a case of peritonitis and an easy-to-perform screening strategy. *J Clin Microbiol.* 36:812-3.

Seenivasan, M. H., and V. L. Yu. 2003. *Staphylococcus lugdunensis* endocarditis--the hidden peril of coagulase-negative staphylococcus in blood cultures. *Eur J Clin Microbiol Infect Dis.* 22:489-91.

### **Erythromycin / Clindamycin and beta-hemolytic Streptococci**

Brown, S. D., and M. J. Rybak. 2004. Antimicrobial susceptibility of *Streptococcus pneumoniae*, *Streptococcus pyogenes* and *Haemophilus influenzae* collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. *J Antimicrob Chemother.* 54 Suppl 1:7-15.

Desjardins, M., K. L. Delgaty, K. Ramotar, C. Seetaram, and B. Toye. 2004. Prevalence and mechanisms of erythromycin resistance in Group A and Group B *Streptococcus*: implications for reporting susceptibility results. *J Clin Microbiol.* 42:5620-3.

Green, M., J. M. Martin, K. A. Barbadora, B. Beall, and E. R. Wald. 2004. Reemergence of macrolide resistance in pharyngeal isolates of Group A streptococci in southwestern Pennsylvania. *Antimicrob Agents Chemother.* 48:473-6.

Hasenbein, M. E., J. E. Warner, K. G. Lambert, S. E. Cole, A. B. Onderdonk, and A. J. McAdam. 2004. Detection of multiple macrolide- and lincosamide-resistant strains of *Streptococcus pyogenes* from patients in the Boston area. *J Clin Microbiol.* 42:1559-63.

Heelan, J. S., M. E. Hasenbein, and A. J. McAdam. 2004. Resistance of group B *Streptococcus* to selected antibiotics, including erythromycin and clindamycin. *J Clin Microbiol.* 42:1263-4.

### **VISA / VRSA**

Appelbaum, P. C., and B. Bozdogan. 2004. Vancomycin resistance in *Staphylococcus aureus*. *Clin Lab Med.* 24:381-402.

Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant *Staphylococcus aureus* containing the *vanA* resistance gene. *N Engl J Med.* 348:1342-7.

Cosgrove, S. E., K. C. Carroll, and T. M. Perl. 2004. *Staphylococcus aureus* with reduced susceptibility to vancomycin. *Clin Infect Dis.* 39:539-45.

Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W.R. Jarvis, T. M. Perl, and F. C. Tenover, for the Vancomycin-Intermediate *Staphylococcus aureus* Epidemiology Study Group. 2003. Epidemiological and microbiological characterization of infections caused by *Staphylococcus aureus* with reduced susceptibility to vancomycin, United States, 1997-2001. *Clin Infect Dis.* 36:429-39.

Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant *Staphylococcus aureus* isolate from a patient in Pennsylvania. *Antimicrob Agents Chemother.* 48:275-280.

Weigel, L. M., D. B. Clewell, S. R. Gill, N. C. Clark, L. K. McDougal, S. E. Flannagan, J. F. Kolonay, J. Shetty, G. E. Killgore, and F. C. Tenover. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of *Staphylococcus aureus*. *Science*. 302:1569-71.

Whitener, C., S. Y. Park, F. Browne, L. Parent, K. Julian, B. Bozdogan, P. Appelbaum, J. Chaitram, L. Weigel, J. Jernigan, L. McDougal, F. Tenover, and S. Fridkin. 2004. Vancomycin-resistant *Staphylococcus aureus* in the absence of vancomycin exposure. *Clin Infect Dis*. 38:1049-1055.

Woods, C., A. Cheng, J. V. Fowler, M. Moorefield, J. Frederick, G. Sakoulas, V. Meka, F. Tenover, P. Zwadyk, and K. Wilson. 2004. Endocarditis caused by *Staphylococcus aureus* with reduced susceptibility to vancomycin. *Clin Infect Dis*. 38:1188-1191.